RecruitingNot ApplicableNCT04674267

Resilience and Equity in Aging, Cancer, and Health (REACH)

Resilience and Equity in Aging, Cancer, and Health (REACH): Promoting Physical Resilience and Cancer Care Equity for Adults Age 70 and Older Diagnosed With Gastrointestinal Malignancy


Sponsor

Dana-Farber Cancer Institute

Enrollment

257 participants

Start Date

Jan 18, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this multi-phase research study is to understand how consultation of cancer care with a geriatrician can best improve outcomes for older adults with gastrointestinal malignancies.


Eligibility

Min Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is examining resilience, equity, and health in older adults aged 70 and over who are being treated for gastrointestinal cancers (cancers of the digestive system, including stomach, colon, pancreas, and liver). Researchers want to understand what factors help older cancer patients do well during treatment and beyond. **You may be eligible if you:** - Are 70 years of age or older at the time of your first consultation - Have been diagnosed with a gastrointestinal cancer (esophagus, stomach, pancreas, liver, bile duct, colon, rectum, anus, or neuroendocrine tumors) - Are continuing your care at Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) - Speak English or Spanish **You may NOT be eligible if you:** - Are younger than 70 at the time of your first consultation - Are not continuing care at DF/BWCC - Do not speak English or Spanish Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPhase 2 Intervention - Geriatric Co-Management

Participants will complete an electronic fitness assessment questionnaire - once completed, they will receive a score of "Robust", "Pre-Frail" or "Frail". Those who are "Pre-frail" or "Frail" will be randomized to meet with a study geriatrician for geriatric co-management in addition to usual oncology care. All participants will be followed for a duration of 1 year.


Locations(1)

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04674267


Related Trials